Genoptix Announces Participation at Investor Conferences in September

Thursday, September 17, 2009 General News J E 4

CARLSBAD, Calif., Sept. 14 Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the following upcoming investor conferences:

On Monday, September 21, 2009, Genoptix COO, Sam Riccitelli, will present at the Bank of America Merrill Lynch Smid Cap Conference at the InterContinental Hotel in Boston, Mass. The presentation will begin at 3:20 p.m. EDT and is expected to last approximately 40 minutes.

On Tuesday, September 22, 2009, Mr. Riccitelli will present at the UBS Global Life Science Conference at the Grand Hyatt in New York City. The presentation is scheduled to begin at 8:30 a.m. EDT, is expected to last approximately 30 minutes and will be followed by a 30 minute break-out session.

Mr. Riccitelli will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance at each of the presentations, which will be web cast live and made accessible through the "Investors" section of the Genoptix website at Those who would like to listen to these presentations should go to this site at least 15 minutes prior to each event to register, download and install any necessary software. A replay will also be available for 30 days following each initial presentation web cast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Alexza Announces Preliminary Results from its AZ-1...
Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Boar...